Compare KIDS & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | NVCT |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.4M | 608.8M |
| IPO Year | 2016 | 2021 |
| Metric | KIDS | NVCT |
|---|---|---|
| Price | $20.88 | $20.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $24.67 | $10.00 |
| AVG Volume (30 Days) | 141.9K | ★ 251.1K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,049,000.00 | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $14.42 | $5.55 |
| 52 Week High | $22.80 | $29.28 |
| Indicator | KIDS | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.17 | N/A |
| Support Level | $15.66 | N/A |
| Resistance Level | $21.40 | N/A |
| Average True Range (ATR) | 0.97 | 0.00 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 82.23 | 0.00 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.